AKBA
Akebia Therapeutics, Inc.
0.8962$
-2.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.5% | 98.7% | 98.7% | 98.4% | 47.0% | 40.1% | 57.7% | 51.2% | 52.0% | 48.9% | 51.6% | 49.1% | |
| 29.5% | 34.8% | 62.4% | 19.3% | 10.5% | 19.2% | 35.6% | 28.3% | 25.4% | 17.8% | 23.5% | 49.1% | |
| 98.1% | 96.9% | 86.7% | 87.2% | 32.3% | 19.2% | 41.8% | 28.3% | 25.4% | 17.8% | 23.5% | 49.1% | |
| 0.0% | – | 11.3% | 9.4% | 1.7% | 5.0% | 4.4% | 9.7% | 11.3% | 16.3% | 15.6% | 12.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 11.5% | 15.1% | 9.5% | 6.9% | 6.1% | 6.5% | 7.4% | 4.1% | |
| 0.2% | 0.4% | 0.9% | 1.0% | 0.8% | 1.3% | 1.3% | 1.3% | 1.5% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 5.5% | 7.1% | 8.5% | 11.2% | 16.6% | 24.4% | 26.8% | 15.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 32.9% | 37.8% | 22.4% | 20.4% | 20.2% | 14.9% | – | – | |
| 6.2% | 8.4% | 77.3% | 67.2% | 36.2% | 48.8% | 61.6% | 86.0% | 98.5% | 112.7% | 122.3% | 91.3% | |
| 6.2% | 8.3% | 38.1% | 39.6% | 26.7% | 27.0% | 29.1% | 49.3% | 36.4% | 41.3% | 36.7% | 43.3% | |
| – | 0.0% | 0.0% | 0.3% | 1.5% | 0.6% | 0.8% | 19.3% | 10.3% | 9.9% | 4.4% | 10.6% | |
| 1.8% | 1.6% | 0.7% | 1.9% | 4.3% | 5.1% | 6.4% | 6.3% | 5.1% | 6.1% | 6.9% | 5.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 10.0% | 15.3% | 0.3% | 9.6% | 7.1% | 17.5% | 12.8% | |
| 93.8% | 91.6% | 22.7% | 32.8% | 63.8% | 51.2% | 38.4% | 14.0% | 1.5% | -12.7% | -22.3% | 8.7% | |
| -90.7% | -112.9% | -99.0% | -102.7% | -51.6% | -103.0% | -182.8% | -276.3% | -437.3% | -665.7% | -760.6% | -447.1% | |
| 13.9% | 18.5% | 12.6% | 11.9% | 11.7% | 15.4% | 21.5% | 31.3% | 51.3% | 77.6% | 95.6% | 68.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.